No Cover Image

Journal article 196 views 107 downloads

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma / Jedd D. Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C. Lance Cowey; Christopher D. Lao; John Wagstaff; Dirk Schadendorf; Pier F. Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S. Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A. Ascierto; Georgina V. Long; Jonathan Cebon; Jeffrey Sosman; Michael A. Postow; Margaret K. Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F. Stephen Hodi; James Larkin

New England Journal of Medicine, Volume: 377, Issue: 14, Pages: 1345 - 1356

Swansea University Author: Wagstaff, John

Check full text

DOI (Published version): 10.1056/NEJMoa1709684

Abstract

This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19%...

Full description

Published in: New England Journal of Medicine
ISSN: 0028-4793 1533-4406
Published: 2017
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa37736
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19% of patients in the Ipi, Nivo and Ipi+Nivo groups respectively. Partial responses were seen in 14, 28 & 29% of patients respectively. With a minimum follow up of 28 months 3 year overall survivals were 32, 52 & 58% in the Ipi, Nivo & Ipi+Nivo respectively. In patients with braf mutations the three year survivals were 37, 56 & 68% in the three groups. This compares with a three year survival of 44% in the dabrafenib plus trametinib arm of the COMBI-D trial (J. Clin. Oncol. 2017 Dob: 10.1200/JCO.2017.74.1025). These data represent practice changing data for oncologist who treat melanoma and life changing treatment for patients with metastatic melanoma.
Keywords: Melanoma, Ipilimumab, Nivolumab, Survival
College: Swansea University Medical School
Issue: 14
Start Page: 1345
End Page: 1356